aTyr Investors Face Dec. 8 Deadline as Rival Lawsuits Over Failed Sarcoidosis Trial Intensify

Overview

• Hagens Berman, Glancy Prongay & Murray, and the Rosen Law Firm are urging shareholders to move for lead‑plaintiff status by December 8, 2025.
• Filed and proposed complaints claim aTyr made materially misleading statements about efzofitimod’s efficacy and the EFZO‑FIT study design, including assertions about fully tapering steroid use.
• Proposed class periods differ, with Hagens Berman citing November 7, 2024 through September 12, 2025, while Rosen defines January 16, 2025 through September 12, 2025.
• The suits follow a September 15 disclosure that EFZO‑FIT failed its primary endpoint on mean daily oral corticosteroid reduction, which drove an intraday share drop of more than 83%.
• aTyr reported third‑quarter GAAP EPS of −$0.26 on $190,000 in revenue and says it plans to meet the FDA in the first quarter of 2026 to discuss efzofitimod’s path forward.